# Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

> **NCT00981799** · PHASE1,PHASE2 · TERMINATED · sponsor: **Therapeutic Advances in Childhood Leukemia Consortium** · enrollment: 23 (actual)

## Conditions studied

- Relapsed T-Cell Acute Lymphoblastic Leukemia
- Relapsed T-Cell Lymphoblastic Lymphoma

## Interventions

- **DRUG:** Nelarabine
- **DRUG:** Etoposide
- **DRUG:** Cyclophosphamide
- **DRUG:** Methotrexate
- **DRUG:** Filgrastim

## Key facts

- **NCT ID:** NCT00981799
- **Lead sponsor:** Therapeutic Advances in Childhood Leukemia Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06
- **Primary completion:** 2015-11
- **Final completion:** 2016-07-18
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Slow accrual rate
- **Last updated:** 2020-10-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00981799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00981799, "Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00981799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*